Selected research
Industry Growth & Trends
Global Primary Myelofibrosis (PMF) Industry Growth and Trends Forecast to 2032
Market perspective
The global Primary Myelofibrosis (PMF) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Primary Myelofibrosis (PMF) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Primary Myelofibrosis (PMF) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Primary Myelofibrosis (PMF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Primary Myelofibrosis (PMF) include GSK, Suzhou Zelgen Biopharmaceuticals, Novartis, Bristol Myers Squibb, AbbVie, Incyte, Grunenthal, CTI BioPharma and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Primary Myelofibrosis (PMF) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Primary Myelofibrosis (PMF) market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Primary Myelofibrosis (PMF) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Primary Myelofibrosis (PMF).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Primary Myelofibrosis (PMF) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Primary Myelofibrosis (PMF) Market by Company
GSK
Suzhou Zelgen Biopharmaceuticals
Novartis
Bristol Myers Squibb
AbbVie
Incyte
Grunenthal
CTI BioPharma
Celgene
Primary Myelofibrosis (PMF) Segment by Type
JAK 1
JAK 2
Others
Primary Myelofibrosis (PMF) Segment by Application
Adults
Children
Primary Myelofibrosis (PMF) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Myelofibrosis (PMF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Primary Myelofibrosis (PMF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Myelofibrosis (PMF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Primary Myelofibrosis (PMF) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Primary Myelofibrosis (PMF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- JAK 1
- JAK 2
- Others
Applications
- Adults
- Children
Companies covered
- GSK
- Suzhou Zelgen Biopharmaceuticals
- Novartis
- Bristol Myers Squibb
- AbbVie
- Incyte
- Grunenthal
- CTI BioPharma
- Celgene
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Primary Myelofibrosis (PMF) Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Primary Myelofibrosis (PMF) Sales Estimates and Forecasts (2021-2032)
- 1.3 Primary Myelofibrosis (PMF) Market by Type
- 1.3.1 JAK 1
- 1.3.2 JAK 2
- 1.3.3 Others
- 1.4 Global Primary Myelofibrosis (PMF) Market Size by Type
- 1.4.1 Global Primary Myelofibrosis (PMF) Market Size Overview by Type (2021-2032)
- 1.4.2 Global Primary Myelofibrosis (PMF) Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Primary Myelofibrosis (PMF) Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Primary Myelofibrosis (PMF) Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Primary Myelofibrosis (PMF) Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Primary Myelofibrosis (PMF) Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Primary Myelofibrosis (PMF) Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Primary Myelofibrosis (PMF) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Primary Myelofibrosis (PMF) Industry Trends
- 2.2 Primary Myelofibrosis (PMF) Industry Drivers
- 2.3 Primary Myelofibrosis (PMF) Industry Opportunities and Challenges
- 2.4 Primary Myelofibrosis (PMF) Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Primary Myelofibrosis (PMF) Revenue (2021-2026)
- 3.2 Global Top Players by Primary Myelofibrosis (PMF) Sales (2021-2026)
- 3.3 Global Top Players by Primary Myelofibrosis (PMF) Price (2021-2026)
- 3.4 Global Primary Myelofibrosis (PMF) Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Primary Myelofibrosis (PMF) Major Company Production Sites & Headquarters
- 3.6 Global Primary Myelofibrosis (PMF) Company, Product Type & Application
- 3.7 Global Primary Myelofibrosis (PMF) Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Primary Myelofibrosis (PMF) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Primary Myelofibrosis (PMF) Players Market Share by Revenue in 2025
- 3.8.3 2025 Primary Myelofibrosis (PMF) Tier 1, Tier 2, and Tier 3
4 Primary Myelofibrosis (PMF) Regional Status and Outlook
- 4.1 Global Primary Myelofibrosis (PMF) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Primary Myelofibrosis (PMF) Historic Market Size by Region
- 4.2.1 Global Primary Myelofibrosis (PMF) Sales in Volume by Region (2021-2026)
- 4.2.2 Global Primary Myelofibrosis (PMF) Sales in Value by Region (2021-2026)
- 4.2.3 Global Primary Myelofibrosis (PMF) Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Primary Myelofibrosis (PMF) Forecasted Market Size by Region
- 4.3.1 Global Primary Myelofibrosis (PMF) Sales in Volume by Region (2027-2032)
- 4.3.2 Global Primary Myelofibrosis (PMF) Sales in Value by Region (2027-2032)
- 4.3.3 Global Primary Myelofibrosis (PMF) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Primary Myelofibrosis (PMF) by Application
- 5.1 Primary Myelofibrosis (PMF) Market by Application
- 5.1.1 Adults
- 5.1.2 Children
- 5.2 Global Primary Myelofibrosis (PMF) Market Size by Application
- 5.2.1 Global Primary Myelofibrosis (PMF) Market Size Overview by Application (2021-2032)
- 5.2.2 Global Primary Myelofibrosis (PMF) Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Primary Myelofibrosis (PMF) Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Primary Myelofibrosis (PMF) Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Primary Myelofibrosis (PMF) Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Primary Myelofibrosis (PMF) Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Primary Myelofibrosis (PMF) Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Primary Myelofibrosis (PMF) Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 GSK
- 6.1.1 GSK Company Information
- 6.1.2 GSK Business Overview
- 6.1.3 GSK Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 GSK Primary Myelofibrosis (PMF) Product Portfolio
- 6.1.5 GSK Recent Developments
- 6.2 Suzhou Zelgen Biopharmaceuticals
- 6.2.1 Suzhou Zelgen Biopharmaceuticals Company Information
- 6.2.2 Suzhou Zelgen Biopharmaceuticals Business Overview
- 6.2.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis (PMF) Product Portfolio
- 6.2.5 Suzhou Zelgen Biopharmaceuticals Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Novartis Primary Myelofibrosis (PMF) Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Bristol Myers Squibb
- 6.4.1 Bristol Myers Squibb Company Information
- 6.4.2 Bristol Myers Squibb Business Overview
- 6.4.3 Bristol Myers Squibb Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Bristol Myers Squibb Primary Myelofibrosis (PMF) Product Portfolio
- 6.4.5 Bristol Myers Squibb Recent Developments
- 6.5 AbbVie
- 6.5.1 AbbVie Company Information
- 6.5.2 AbbVie Business Overview
- 6.5.3 AbbVie Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 AbbVie Primary Myelofibrosis (PMF) Product Portfolio
- 6.5.5 AbbVie Recent Developments
- 6.6 Incyte
- 6.6.1 Incyte Company Information
- 6.6.2 Incyte Business Overview
- 6.6.3 Incyte Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Incyte Primary Myelofibrosis (PMF) Product Portfolio
- 6.6.5 Incyte Recent Developments
- 6.7 Grunenthal
- 6.7.1 Grunenthal Company Information
- 6.7.2 Grunenthal Business Overview
- 6.7.3 Grunenthal Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Grunenthal Primary Myelofibrosis (PMF) Product Portfolio
- 6.7.5 Grunenthal Recent Developments
- 6.8 CTI BioPharma
- 6.8.1 CTI BioPharma Company Information
- 6.8.2 CTI BioPharma Business Overview
- 6.8.3 CTI BioPharma Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 CTI BioPharma Primary Myelofibrosis (PMF) Product Portfolio
- 6.8.5 CTI BioPharma Recent Developments
- 6.9 Celgene
- 6.9.1 Celgene Company Information
- 6.9.2 Celgene Business Overview
- 6.9.3 Celgene Primary Myelofibrosis (PMF) Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Celgene Primary Myelofibrosis (PMF) Product Portfolio
- 6.9.5 Celgene Recent Developments
7 North America by Country
- 7.1 North America Primary Myelofibrosis (PMF) Sales by Country
- 7.1.1 North America Primary Myelofibrosis (PMF) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Primary Myelofibrosis (PMF) Sales by Country (2021-2026)
- 7.1.3 North America Primary Myelofibrosis (PMF) Sales Forecast by Country (2027-2032)
- 7.2 North America Primary Myelofibrosis (PMF) Market Size by Country
- 7.2.1 North America Primary Myelofibrosis (PMF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Primary Myelofibrosis (PMF) Market Size by Country (2021-2026)
- 7.2.3 North America Primary Myelofibrosis (PMF) Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Primary Myelofibrosis (PMF) Sales by Country
- 8.1.1 Europe Primary Myelofibrosis (PMF) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Primary Myelofibrosis (PMF) Sales by Country (2021-2026)
- 8.1.3 Europe Primary Myelofibrosis (PMF) Sales Forecast by Country (2027-2032)
- 8.2 Europe Primary Myelofibrosis (PMF) Market Size by Country
- 8.2.1 Europe Primary Myelofibrosis (PMF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Primary Myelofibrosis (PMF) Market Size by Country (2021-2026)
- 8.2.3 Europe Primary Myelofibrosis (PMF) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Primary Myelofibrosis (PMF) Sales by Country
- 9.1.1 Asia-Pacific Primary Myelofibrosis (PMF) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Primary Myelofibrosis (PMF) Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Primary Myelofibrosis (PMF) Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Primary Myelofibrosis (PMF) Market Size by Country
- 9.2.1 Asia-Pacific Primary Myelofibrosis (PMF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Primary Myelofibrosis (PMF) Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Primary Myelofibrosis (PMF) Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Primary Myelofibrosis (PMF) Sales by Country
- 10.1.1 South America Primary Myelofibrosis (PMF) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Primary Myelofibrosis (PMF) Sales by Country (2021-2026)
- 10.1.3 South America Primary Myelofibrosis (PMF) Sales Forecast by Country (2027-2032)
- 10.2 South America Primary Myelofibrosis (PMF) Market Size by Country
- 10.2.1 South America Primary Myelofibrosis (PMF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Primary Myelofibrosis (PMF) Market Size by Country (2021-2026)
- 10.2.3 South America Primary Myelofibrosis (PMF) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Primary Myelofibrosis (PMF) Sales by Country
- 11.1.1 Middle East and Africa Primary Myelofibrosis (PMF) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Primary Myelofibrosis (PMF) Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Primary Myelofibrosis (PMF) Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Primary Myelofibrosis (PMF) Market Size by Country
- 11.2.1 Middle East and Africa Primary Myelofibrosis (PMF) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Primary Myelofibrosis (PMF) Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Primary Myelofibrosis (PMF) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Primary Myelofibrosis (PMF) Value Chain Analysis
- 12.1.1 Primary Myelofibrosis (PMF) Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Primary Myelofibrosis (PMF) Production Mode & Process
- 12.2 Primary Myelofibrosis (PMF) Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Primary Myelofibrosis (PMF) Distributors
- 12.2.3 Primary Myelofibrosis (PMF) Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst